Monthly Cost Comparison: Wegovy vs Mounjaro Pricing
What Is Better Mounjaro or Wegovy: Understanding Monthly Cost Structures
When evaluating what is better Mounjaro or Wegovy from a monthly cost perspective, understanding each treatment's escalation schedule proves essential for accurate budgeting. Wegovy follows a structured 16-week dose escalation from 0.25mg to the maintenance dose of 2.4mg, with monthly costs ranging from £79.99 to £209.99. This predictable pricing structure allows patients to plan their treatment expenses across the initial four months before reaching the consistent maintenance cost.
Mounjaro follows a different escalation pattern with its own pricing framework, typically requiring 20 weeks to reach maintenance doses. The question of what is better Mounjaro or Wegovy often depends on individual tolerance, clinical response, and long-term affordability of the maintenance phase. Both treatments represent significant monthly investments, making cost transparency and prescriber guidance crucial for sustainable weight management success.
Wegovy Monthly Pricing Breakdown: Complete Cost Analysis
Understanding Wegovy's monthly costs requires examining each escalation phase systematically. Month one begins at £79.99 for the 0.25mg starter dose using code FIRST40, progressing to £94.99 for 0.5mg in month two, then £99.99 for 1mg in month three, and £139.99 for 1.7mg in month four. From month five onwards, patients reach the maintenance dose of 2.4mg at £209.99 monthly, with returning customers benefiting from code DOSE25 applied at checkout.
Annual maintenance costs total approximately £2,520 for continuous 2.4mg treatment, representing a significant but predictable investment in long-term weight management. EverydayMeds offers convenience bundles like the Ultimate Stability Trio providing three months of 2.4mg supply for £649.99, ensuring uninterrupted treatment without monthly reordering. These pricing structures reflect the prescription-only medicine's clinical development costs and specialist manufacturing requirements for the FlexTouch pen delivery system.
Clinical Evidence: What Is Better Mounjaro or Wegovy Based on Trial Data
Clinical trials provide factual evidence for evaluating what is better Mounjaro or Wegovy, though direct head-to-head comparisons remain limited due to different trial designs and populations. The STEP trials demonstrated that patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in STEP 1, with sustained results of 15.2% at two years in STEP 5. The SELECT trial additionally showed a 20% reduction in major cardiovascular events.
Mounjaro's SURMOUNT trials showed different weight loss patterns, though comparing percentages directly would be inappropriate given varying trial methodologies and patient populations. Both treatments demonstrated efficacy in their respective clinical programmes when used as prescription-only medicines alongside appropriate lifestyle interventions. Individual clinical response varies significantly, making prescriber assessment essential for determining which treatment may be more suitable based on medical history, tolerance, and treatment goals.
How Wegovy Works: GLP-1 Mechanism and Monthly Treatment Cycle
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones to support weight management goals. The medication works by reducing appetite, promoting feelings of fullness after smaller meals, and may help reduce food cravings by acting on brain appetite centres. This once-weekly injectable treatment requires systematic dose escalation over 16 weeks to minimise gastrointestinal side effects while optimising therapeutic benefit. Each monthly supply contains four pre-filled FlexTouch pens for convenient self-administration, designed for subcutaneous injection into the thigh, upper arm, or abdomen. The gradual dose increases allow the body to adapt to higher semaglutide levels, supporting sustainable weight management when combined with reduced-calorie diet and increased physical activity.
EverydayMeds Ordering Process: From Assessment to Monthly Delivery
Accessing Wegovy through EverydayMeds begins with a comprehensive three-minute online clinical assessment covering medical history, current medications, and weight management goals. Our prescribers review each application within standard three working days, with express 24-hour review available for urgent requirements. Once approved, your first monthly supply ships via next-day cold-chain delivery, maintaining the essential 2-8°C temperature requirements throughout transit. Subsequent monthly orders can be scheduled automatically or placed as needed, with returning customers benefiting from code DOSE25 for ongoing savings. Our GPhC-registered pharmacy (#9012878) ensures all Wegovy supplies meet UK regulatory standards, with clinical support available throughout your treatment journey for dosing guidance, side effect management, and ongoing monitoring requirements.
Storage and Practical Considerations: Monthly Supply Management
Each monthly Wegovy supply requires refrigeration at 2-8°C before first use, though the FlexTouch pens maintain stability for up to six weeks at room temperature below 30°C once removed from cold storage. This storage advantage over Mounjaro's 21-day room temperature limit provides greater flexibility for travel and daily routine management. The pre-filled pen design eliminates reconstitution requirements, with clear dose markings and automatic needle insertion for consistent weekly administration. Monthly supplies arrive in temperature-controlled packaging with storage instructions and disposal guidance for used pens. Patients should rotate injection sites weekly and maintain a consistent injection day, typically scheduling deliveries to arrive several days before their current supply expires. The prescription-only medicine requires ongoing prescriber oversight, with monthly assessments ensuring treatment remains appropriate and effective for individual weight management goals.
What Is Better Mounjaro or Wegovy: Long-term Monthly Budget Planning
Long-term financial planning for either treatment requires understanding that weight management represents an ongoing commitment rather than a temporary intervention. STEP trial extensions demonstrated that patients regained approximately two-thirds of weight lost within one year of stopping treatment, emphasising the chronic nature of obesity management. Monthly budgeting should therefore account for extended treatment periods, with maintenance dose costs representing the true long-term investment.
For Wegovy, maintenance costs of £209.99 monthly translate to annual expenses of approximately £2,520, while Mounjaro's maintenance pricing follows different structures. The question of what is better Mounjaro or Wegovy often depends on individual insurance coverage, treatment response, and long-term affordability planning. EverydayMeds offers flexible ordering options including multi-month bundles that can reduce monthly administrative overhead while ensuring continuous supply availability.
Treatment Selection Support: Clinical Guidance for Mounjaro vs Wegovy Choice
Both Wegovy and Mounjaro are available from EverydayMeds, with prescribers helping determine which treatment aligns better with individual medical profiles and budget requirements. Clinical assessment considers factors including previous GLP-1 experience, gastrointestinal tolerance, injection frequency preferences, and monthly cost sustainability over extended periods. Wegovy's once-weekly dosing and established clinical evidence base appeal to many patients, while Mounjaro's dual-receptor mechanism may suit others better based on prescriber evaluation. Our clinical team provides ongoing support for treatment optimisation, side effect management, and cost-effective prescribing decisions. The prescription-only nature of both treatments ensures appropriate medical oversight throughout your weight management journey, with monthly check-ins helping adjust treatment plans based on progress and tolerance. Treatment selection ultimately depends on individual clinical response, tolerability, and long-term commitment to monthly treatment costs alongside lifestyle modifications.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
